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ABSTRACT
Few studies have tested the benefits of using peripheral blood stem cell (PBSC) grafts versus bone marrow (BM)
grafts for unrelated donor transplantation. Yet there has been a substantial change in clinical practice, with
increasing numbers of adults receiving unrelated donor PBSC grafts. We compared outcomes after 331 PBSC and
586 BM transplants in adults with leukemia and myelodysplastic syndrome (MDS) who were followed for a median
of 3 years after transplantation. PBSC recipients were less likely to have chronic myelogenous leukemia (CML) and
more likely to have MDS, to have poor performance scores, and to be transplanted more recently. Outcomes were
analyzed using Cox regression models. Rates of grades 2-4 acute graft-versus-host disease (GVHD) (58% versus
45%, P < .001) and chronic GVHD (cGVHD) (56% versus 42%, P < .001) were significantly higher with PBSC
than with BM transplants. Rates of grade II-IV aGVHD were similar with PBSC and BM transplants. The 3-year
probabilities of treatment-related mortality (TRM), leukemia recurrence, leukemia-free, and overall survival (OS)
were similar in the 2 groups with 3-year leukemia-free survival rates of 30% and 32% after transplantation of PBSC
and BM, respectively. Unlike results after HLA-matched sibling donor PBSC transplants, we did not identify a
survival advantage with PBSC grafts in patients receiving unrelated donor transplants for advanced leukemia. The
higher rate of cGVHD after PBSC transplants and, consequently, more frequent late adverse events warrant
extended follow up of PBSC recipients.
© 2007 American Society for Blood and Marrow Transplantation
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Peripheral blood stem cells (PBSCs) are increas-
ingly used for related and unrelated donor hemato-
poietic stem cell transplantation (HSCT). Collection
of PBSC rather than bone marrow (BM) offers several
advantages to the donor, namely, avoidance of anes-
thesia, hospitalization, and potential exposure to
blood products, although controlled comparisons of
PBSC and BM donation do not indicate substantialdifferences in serious adverse effects. There are nu-
merous reports, including randomized trials, compar-
ing recipient outcomes after PBSC and BM trans-
plants from HLA-matched sibling donors [1-4].
Although these studies support a survival advantage
with PBSC in recipients transplanted for advanced
leukemia, a convincing survival advantage for those
with early leukemia is not documented. Most data
indicate a higher risk of chronic graft-versus-host dis-1461
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with BM grafts [5,6]. There are few data available
regarding outcomes of PBSC and BM transplants
from unrelated donors, and none have shown lower
survival rates after PBSC transplants [7-10]. Data
from the National Marrow Donor Program (NMDP)
indicates that approximately 80% of unrelated donor
transplants in adults in the United States now use
PBSC grafts. Therefore, to address the role of PBSC
grafts, we analyzed data on 331 recipients of unrelated
donor PBSC and 586 recipients of unrelated donor
BM transplants facilitated by the NMDP in the
United States in 2000-2003, and reported to the Cen-




A formal afﬁliation of the research division of the
NMDP (established in 1986) and the International
Bone Marrow Transplant Registry (established in
1972) led to the establishment of the CIBMTR in
2004. The CIBMTR is a working group of 500
transplant centers worldwide that voluntarily contrib-
ute data on allogeneic transplant recipients to a Sta-
tistical Center at the Medical College of Wisconsin.
Participating centers register and provide basic infor-
mation on all consecutive transplantations. Detailed
demographic, disease, and transplant characteristics
and outcome data are collected on all unrelated donor
transplantations facilitated by the NMDP in the
United States. Patients are followed longitudinally.
Computerized error checks, physician review of sub-
mitted data, and on-site audits of participating centers
ensure data quality.
Inclusion Criteria
The study included patients 18-60 years of age
who received PBSC or BM grafts from a volunteer
unrelated donor for acute lymphoblastic leukemia
(ALL), acute myelogenous leukemia (AML), myelo-
dysplastic syndrome (MDS), or chronic myelogenous
leukemia (CML) in the United States. All transplants
were facilitated by the NMDP between January 1,
2000, and December 31, 2003, and donor-recipient
pairs had to have allele-level typing at HLA-A, -B, -C,
and -DRB1. Excluded were recipients of T cell-de-
pleted BM or CD34 selected PBSC grafts and reduced
intensity (RIC) preparative regimens. We deﬁned
RIC regimens as follows: busulfan dose 9 mg/kg,
melphalan dose 150 mg/m2, and total body irradia-
tion (TBI) dose 500 cGy (single or fractionated) or
500-800 cGy (fractionated).
The NMDP retrospectively obtained consent for
data submission and study participation from surviv-ing patients or their parent/legal guardian for trans-
plantations it facilitated in the United States during
the study period; the NMDP institutional review
board waived consent for patients who had died prior
to soliciting consent. To address bias introduced by
inclusion of only a proportion of surviving patients
(those who consented) but all deceased recipients, a
sample of deceased patients was selected using a
weighted randomized scheme that adjusts for over-
representation of deceased patients in the consented
cohort. This weighted randomized scheme was devel-
oped based on all survivors in the NMDP database. A
logistic regression model was ﬁt to identify factors
that predicted whether patients had consented or not
consented to use of data collected by the NMDP. This
analysis found the following factors were associated
with the likelihood of a patient consenting: age, dis-
ease type, race, sex, cytomegalovirus (CMV) serologic
status, and country of transplantation (United States
versus non-United States). Using estimated con-
senting probabilities from this model based on the
characteristics of dead patients, a biased coin method
of randomization was performed to determine which
dead patients are included in the ﬁnal sample. Thus,
this procedure ensures that the preconsented dead
patients are included in the sample with the same
probability as the survivors who actually consented to
participate in the study. Approximately 13% of the
surviving patients failed to consent, and 12% of the
dead patients were deleted by the weighted random-
ized method. The above-described method was tested
several times, and on every occasion the proportion of
deleted dead patients was similar [11]. Each sample
gave essentially the same set of regression parameters
and survival estimates.
Endpoints
Neutrophil recovery was deﬁned as achieving an
absolute neutrophil count (ANC) of  500 cells per
cubic millimeter for 3 consecutive days; platelet re-
covery was deﬁned as achieving 20,000 platelets per
cubic millimeter, unsupported by transfusions for 7
days. Incidences of grades II, III, and IV acute GVHD
(aGVHD) and cGVHD were determined in all pa-
tients [12-14]. Treatment-related mortality (TRM)
was deﬁned as death during a continuous remission.
Relapse was deﬁned as recurrence of leukemia (hema-
tologic); patients in whom a remission failed to occur
after transplantation were considered to have had a
recurrence at day 1. Leukemia-free survival was de-
ﬁned as survival in a state of continuous complete
remission.
Statistical Analysis
Variables related to patient, disease, and transplant
characteristics were compared using the chi-square
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for continuous variables. Probabilities of overall (OS)
and leukemia-free survival were calculated using the
Kaplan-Meier estimator [15]. For analyses of survival,
death from any cause was considered an event, and
data on surviving patients were censored at last follow-
up. For analyses of leukemia-free survival, relapse or
death (ie, treatment failure) was considered an event,
and data for patients alive in continuous remission
were censored at last follow-up. Probabilities of neu-
trophil and platelet recovery, aGVHD and cGVHD,
TRM, and relapse were calculated using the cumula-
tive-incidence-function [15]. For neutrophil and
platelet recovery and GVHD, death without an event
(hematopoietic recovery or GVHD) was the compet-
ing event. For TRM (death in continuous complete
remission), relapse was the competing event. For re-
lapse, treatment-related death was the competing
event. Data on patients without either competing
event were censored at last follow-up. Conﬁdence
intervals were calculated with the use of a log-trans-
formation [15]. Adjusted probabilities of OS and leu-
kemia-free survival were estimated by Cox’s propor-
tional hazards regression model [16].
Multivariate models were built using a stepwise
forward selection technique, using a P-value of .05 or
less as the criterion for inclusion in the ﬁnal model.
The primary objective was to compare outcomes ac-
cording to graft type, PBSC versus BM; this variable
was included in all models. Other variables considered
in the analyses were donor and recipient age, perfor-
mance score pretransplant, serologic status of the
donor and recipient with respect to cytomegalovirus
(CMV) before transplantation, sex of the donor and
recipient, type of leukemia (ALL versus AML versus
MDS versus CML), disease status at transplantation
(ﬁrst complete clinical remission [CCR], ﬁrst
chronic phase [CP], refractory anemia versus other),
conditioning regimen (TBI versus none), GVHD
prophylaxis (cyclosporine-based versus tacrolimus-
based), and HLA disparity (matched at HLA-A, -B,
-C, and DRB1 versus 1-allele mismatch versus 2-al-
lele mismatch). All possible risk factors were
checked for proportional hazards using a time-de-
pendent covariate approach, and there were no vi-
olations to the proportionality assumption. There
were no ﬁrst-order interactions between graft type
and these other variables. There were no statisti-
cally signiﬁcant center effects [17]. P-values are
2-sided. Completeness of follow-up (the ratio of the
sum of the observed follow up time to the sum of
the potential follow up time for all patients in the
study) for the study population was 97% [18]. Anal-
yses were completed with the use of SAS software,
version 9.1 (SAS Institute, Cary, NC).RESULTS
Patients
Table 1 shows patient, disease, and transplant
characteristics. Compared with BM recipients, PBSC
recipients were less likely to have CML, more likely to
have MDS, more likely to have a poor performance
score pretransplantation, and were transplanted more
recently. We observed no differences in patient selec-
tion with respect to disease status at transplantation.
We could not examine whether cytogenetic risk clas-
siﬁcation affected the choice of graft type, as this data
is not available for 2 of 3 of the patients with acute
leukemia. The median total nucleated cell dose of
PBSC grafts was higher than that of BM grafts (6.7 
108/kg, range, 2.0-25.2 versus 2.9  108/kg, range,
1.0-21.8, P .001). The median period of follow-up
for survivors after PBSC and BM transplantation was
34 and 38 months, respectively.
Hematopoietic Recovery
The probability of neutrophil recovery at day 28
was higher after transplantation of PBSC than after
BM, 94% (95% CI 91-96) and 87% (95% CI 84-90),
respectively, P .001. Sixteen of 311 PBSC recipients
and 55 of 531 BM recipients did not achieve neutro-
phil recovery. Similarly, platelet recovery at day 100
was higher after PBSC than after BM transplants,
80% (95% CI 75-84) and 69% (95% CI 65-72), re-
spectively, P  .001. A similar trend was observed at 1
year (82% [95% CI 77-86] versus 72% [95% CI
68-76], P  .001). Fifty-nine of 330 PBSC recipients
and 162 of 586 BM recipients did not achieve platelet
recovery.
GVHD
Grade II-IV aGVHD occurred in 194 of 330
PBSC and 268 of 585 BM recipients; risks of grade
II-IV aGVHD were higher after transplantation of
PBSC than BM (relative risk [RR] 1.50, 95% CI
1.27-1.81, P .001). Grade III-IV aGVHD risks were
similar in the 2 groups (RR 1.17, 95% CI 0.90-1.51,
P  .249). The day 100 probabilities of grade II-IV
aGVHD were 58% (95% CI 53-64) and 45% (95%
CI 41-49) after transplantation of PBSC and BM,
respectively, P  .001 (Figure 1). Corresponding
probabilities of grade III-IV aGVHD were 28% (95%
CI 24-33) and 25% (95% CI 21-28).
cGVHD occurred in 186 of 331 PBSC and 249 of
586 BM recipients. Risks of cGVHD were signiﬁ-
cantly higher after transplantation of PBSC than after
BM (RR 1.72, 95% CI 1.41-2.10, P  .001). The
severity of cGVHD did not differ by graft type. The
3-year probabilities of cGVHD were 56% (95% CI
51-61) and 42% (95% CI 38-46) after PBSC and BM
transplants, respectively, P  .001 (Figure 2).
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Peripheral Blood Stem Cells Bone Marrow
P-ValueCharacteristics of Patients Number (%) Number (%)
Number of patients 331 586
Age at transplant, years .141
18-30 85 (26) 168 (29)
31-40 79 (24) 147 (25)
41-50 104 (31) 193 (33)
51-60 63 (19) 78 (13)
Male recipient 184 (56) 317 (54) .663
Performance score .005
90-100 111 (34) 384 (66)
10-80 181 (55) 150 (26)
Unknown 39 (12) 52 (9)
Disease .007
ALL 77 (23) 138 (24)
AML 143 (43) 225 (38)
CML 66 (20) 170 (29)
MDS 45 (14) 53 (9)
Disease status
AML .006
CR1 47 (33) 62 (28)
CR2 49 (34) 114 (51)
Relapse 47 (33) 49 (22)
ALL .299
CR1 28 (36) 45 (33)
CR2 37 (48) 59 (43)
Relapse 12 (16) 34 (25)
MDS .038
RA 20 (44) 13 (25)
RAEB/RAEBT 25 (56) 40 (75)
CML .019
CP1 28 (42) 103 (60)
CP2, AP 33 (50) 52 (31)
Blast phase 5 (8) 15 (9)
Year of infusion <.001
2000 45 (14) 220 (38)
2001 77 (23) 158 (27)
2002 77 (23) 96 (16)
2003 132 (40) 112 (19)
Conditioning regimen .061
TBI regimen 232 (70) 444 (76)
Busulfan  cyclophosphamide 99 (30) 142 (24)
GVHD Prophylaxis .500
Tacrolimus  other 163 (49) 275 (47)
Cyclosporine  other 168 (51) 311 (53)
Donor age at transplant, years .178
18-30 102 (31) 204 (35)
31-40 126 (38) 221 (38)
41-50 74 (22) 130 (22)
51-60 29 (9) 31 (5)
Donor-recipient sex match .330
Male ¡ Male 113 (34) 215 (37)
Male ¡ Female 79 (24) 159 (27)
Female ¡ Male 71 (21) 102 (17)
Female ¡ Female 68 (21) 110 (19)
Donor-recipient CMV status .104
Donor ()/Recipient () 90 (27) 192 (33)
Donor ()/Recipient () 99 (30) 155 (26)
Donor ()/Recipient () 50 (15) 74 (13)
Donor ()/Recipient () 59 (18) 134 (23)
Unknown 33 (10) 31 (5)
HLA-A, -B, -C, -DRB1 (allele-level typing) .967
Matched 192 (58) 341 (58)
1-allele mismatch 62 (11) 44 (13)
>2-allele mismatch 183 (32) 95 (29)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; TBI, total body irradiation; CR, complete clinical remission; CP, chronic phase; AP, accelerated phase; GVHD, graft-versus-host
disease; CMV, cytomegalovirus; RAEB/RAEBT, refractory anemia with excess blasts or in transformation; HLA, human leukocyte antigen.
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l blood stem cell (PBSC) and bone marrow (BM) transplants.Transplant-Related Mortality (TRM)
TRM rates were similar after PBSC and BM
transplants (Tables 2 and 3). Early (within 3 months)
TRM rates were similar after PBSC and BM trans-
plants, 22% (95% CI 18-27) and 26% (95% CI 24-
28), respectively. Corresponding 3-year probabilities
were 44% (95% CI 38-50) and 44% (95% CI 40-48)
after PBSC and BM transplants, respectively.
Relapse
Relapse rates were similar after transplantation of
PBSC and BM regardless of type of leukemia or
whether the transplantation was done for early, inter-
mediate, or advanced disease (Tables 2 and 3). The
3-year probabilities of relapse were 26% (95% CI
21-31) and 24% (95% CI 21-28) after PBSC and BM
transplants, respectively.
Leukemia-Free Survival
Risks of treatment failure were similar after trans-
plantation of PBSC and BM regardless of type of
leukemia or whether the transplantation was done for
Figure 1. Probability of grade II-IV aGVHD after peripheraearly, intermediate, or advanced disease (Table 2
and 3). The 3-year probabilities of leukemia-free
survival were 30% (95% CI 25-36) and 32% (95%
CI 28-36) after PBSC and BM transplants, respec-
tively (Figure 3).
Overall Mortality
Overall, deaths occurred in 216 of 331 PBSC and
384 of 586 BM recipients. Risks of overall mortality
were similar after transplantation of PBSC and BM
(Table 2). However, for patients with good risk CML
(ﬁrst chronic phase), overall mortality rates appear to
be higher after PBSC transplants (Table 3). The
3-year probabilities of OS were 32% (95% CI 26-37)
and 33% (95% CI 29-37) after PBSC and BM trans-
plants, respectively. There were no differences in
causes of death by graft type. Causes of death included
recurrent leukemia (36% versus 33%), GVHD (14%
vervus 13%), interstitial pneumonitis (8% versus 8%),
infections (18% versus 20%), organ failure (13% ver-
sus 14%), and other causes (11% versus 12%) afterFigure 2. Probability of cGVHD after peripheral blood stem cell (PBSC) and bone marrow (BM) transplants.
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Our primary objective was to compare the effec-
tiveness of transplantation of PBSC and BM grafts
from unrelated donors in adults with leukemia and
Table 2. Results of Multivariate Analysis of Transplant Outcomes







Bone marrow 577 1.00
Peripheral blood stem cells 327 0.89 (0.73-1.10) .293
Relapse
Bone marrow 577 1.00
Peripheral blood stem cells 327 0.99 (0.74-1.31) .938
Treatment failure
Bone marrow 577 1.00
Peripheral blood stem cells 327 0.92 (0.78-1.09) .352
Overall mortality
Bone marrow 586 1.00
Peripheral blood stem cells 331 0.92 (0.78-1.09) .359
N indicates number of evaluable recipients.
The relative risks shown above are adjusted for the following:
Transplant related mortality: performance score at transplant, do-
nor-recipient cytomegalovirus status, recipient age, and donor-
recipient HLA-match.
Relapse: leukemia type, disease status at transplant and donor-
recipient HLA-match.
Treatment failure and overall mortality: performance score at trans-
plant, recipient age, leukemia type, disease status at transplant,
donor-recipient cytomegalovirus status, and HLA-match.MDS. Despite faster hematopoietic recovery after
PBSC transplantation, the net differences in the
3-year probabilities of TRM, relapse, leukemia-free
survival, and OS between the groups were negligible.
Transplantation of PBSC was associated with higher
grade II-IV aGVHD and cGVHD than transplanta-
tion of BM. Mortality rates were higher in recipients
with cGVHD regardless of the type of graft used for
transplantation.
The results of this analysis, indicating higher
GVHD rates without a survival advantage, suggest a
need for randomized clinical trials to better deﬁne the
role of PBSC grafts in unrelated donor transplanta-
tion. Published data in this area are few [7-10]. Unlike
2 other reports of unrelated donor PBSC transplants
[8,10], we observed higher cGVHD rates after PBSC
transplants compared to BM transplants, but with a
similar proportion of patients with extensive cGVHD
in both groups. The probability of cGVHD after
PBSC and BM transplants reported by Remberger
and colleagues [10] was higher than in the current
report. The etiology for the higher rate of cGVHD in
their population of patients is not readily explained. In
this report, transplantations were more recent (2000-
2003), 60% of patients in both treatment groups were
matched (allele-level) at HLA-A, -B, -C, and DRB1,
and approximately 50% received tacrolimus-contain-
ing regimen for GVHD prophylaxis. The patients
reported by Remberger and colleagues [10] were
transplanted earlier and patients and donors were
matched at HLA A, B (low resolution), and DRB1.Table 3. Results of Multivariate Analysis of Transplant Outcomes After Unrelated Donor Peripheral Blood Stem Cell And Bone Marrow
Transplantations by Leukemia Type and Disease Status at Transplantation
Outcome N1/N2 Relative Risk* (95% Confidence Interval) P-Value
Transplant-related mortality
AL/MDS, CR1, RA 95/119 0.78 (0.52-1.19) .256
AL/MDS, CR2, Relapse, RAEB, RAEBT 170/296 0.86 (0.65-1.16) .328
CL, CP1 28/103 1.71 (0.97-3.01) .062
CL, CP2, AP, BP 38/67 0.97 (0.49-1.90) .928
Relapse
AL/MDS, CR1, RA 95/119 0.83 (0.44-1.55) .554
AL/MDS, CR2, Relapse, RAEB, RAEBT 170/296 0.85 (0.60-1.19) .345
CL, CP1 28/103 0.76 (0.09-6.31) .800
CL, CP2, AP, BP 38/67 1.30 (0.64-2.64) .462
Treatment failure
AL/MDS, CR1, RA 95/119 0.78 (0.55-1.11) .172
AL/MDS, CR2, Relapse, RAEB, RAEBT 170/296 0.85 (0.68-1.06) .151
CL, CP1 28/103 1.64 (0.95-2.82) .074
CL, CP2, AP, BP 38/67 1.12 (0.69-1.82) .650
Overall mortality
AL/MDS, CR1, RA 95/119 0.78 (0.55-1.11) .174
AL/MDS, CR2, Relapse, RAEB, RAEBT 170/296 0.86 (0.68-1.07) .174
CL, CP1 28/103 1.89 (1.09-3.27) .023
CL, CP2, AP, BP 38/67 0.96 (0.58-1.59) .889
N1 indicates number of evaluable PBSC recipients; N2, number of evaluable BM recipients; AL, acute leukemia; MDS, myelodysplastic
syndrome; CL, chronic myeloid leukemia; CR, clinical remission; RA, refractory anemia; RAEB/RAEBT, refractory anemia with blasts or
in transformation; CP, chronic phase; AP, accelerated phase; BP, blast phase.
*Baseline: bone marrow; relative risk of 1.00 and P  .05 indicate an advantage for peripheral blood stem cell.
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these patients will be mismatched at HLA-A and/or
-B, and 92% will carry at least 1 allele-mismatch at 1
of the 8 loci [19].
The presumed protective effect of GVHD in pre-
venting recurrent leukemia was not observed in this
study and that of others [7-10], even though rates of
aGVHD and cGVHD were signiﬁcantly higher after
PBSC transplants. Garderet and colleagues [9] ob-
served lower leukemia-free survival rates in patients
with ALL, a trend not observed in the current analysis
or other reports [7,8,10]. As expected, disease status at
transplantation adversely affected leukemia relapse,
OS, and leukemia-free survival regardless of the type
of graft. There was no overall advantage in survival for
1 graft type over another in patients with intermediate
and advanced leukemia at transplantation. This is con-
sistent with other reports of unrelated donor PBSC
transplants [7-10], but differs from transplantation of
PBSC grafts from HLA-matched sibling donors
where patients with advanced leukemia appear to ben-
eﬁt from PBSC grafts [1-4]. There might be a GVHD
threshold above which there is no additional beneﬁt
from graft-versus-leukemia (GVL) responses, and
with unrelated donor transplantation such a threshold
may be achieved with BM grafts.
It remains to be seen whether, with longer follow-
up, the observed higher aGVHD and cGVHD after
unrelated donor PBSC transplants will adversely af-
fect long-term survival in good-risk patients with
CML as observed after HLA-matched sibling donor
PBSC transplants [20]. In the current report, mortal-
ity rates appear to be higher after PBSC transplants in
patients with good-risk CML. As there are only 28
PBSC recipients in this group our ﬁndings must be
conﬁrmed in a larger series and preferably a ran-
domized clinical trial. Extended follow-up of the
current cohort may also better deﬁne the role of
PBSC grafts and is planned. We did not perform
Figure 3. Probability of leukemia-free survival after peripheranalysis of total nucleated cell dose or CD34 cell
dose, as these are surrogates for graft type. PBSC
recipients received higher cell doses compared to
BM recipients. Nevertheless, most BM recipients
received a cell dose adequate to achieve hematopoi-
etic recovery.
All aspects of the transplantation regimen includ-
ing choice of graft were determined by transplant
centers. Any observational study of a therapeutic in-
tervention is subject to bias owing to the complex
selection process that underlies the choice of interven-
tion, and our study is no exception. Nevertheless, our
ability to adjust for key risk factors made a controlled
comparison of the groups possible. Additionally, ran-
domized trials to compare these 2 graft types from
unrelated donors are necessary. One such trial, spon-
sored by the Blood and Marrow Transplant Clinical
Trials Network was initiated in 2004. This study is
expected to enroll 550 patients over the next 3 years
with extensive evaluation of both donor and recipient
outcomes.
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